Articles From: ARI Promotes Bradley J. Smith to Vice President of Product Management to ARIAD Reports Second Quarter 2013 Financial Results and Development Progress


2014/2/13
MILWAUKEE, Feb.
Sign-up for ARI Promotes Bradley J. Smith to Vice President of Product Management investment picks
2014/1/2
MILWAUKEE, Jan.
Sign-up for ARI to Hold Annual Shareholder Meeting January 7, 2014 investment picks
2014/2/11
MILWAUKEE, Feb.
Sign-up for ARI to Provide Its Award-Winning Websites to KYMCO USA Dealers investment picks
2014/3/19
NEW YORK , March 19, 2014 /PRNewswire/ -- Oppenheimer & Co.
Sign-up for Ari Wald Joins Oppenheimer's Portfolio Strategy Team As Executive Director And Market Technician investment picks
2014/2/21
MILWAUKEE, Feb.
Sign-up for ARI's AccessorySmart(TM) Receives Prestigious Nifty 50 Award investment picks
The law firm of Wohl & Fruchter LLP is investigating possible violations of federal securities laws by officers and directors of Ariad Pharmaceuticals Inc. (Ariad) (NASDAQ:ARIA). On October 9, 2013, Ariad announced that its leukemia drug Iclusig causes more blood clots and heart-related side effects than previously reported, forcing the company to halt enrollment in Iclusig clinical trials and advise patients currently on the drug to lower the dose.
Sign-up for ARIA SHAREHOLDER ALERT: The Law Firm of Wohl & Fruchter LLP Announces Investigation of Ariad Pharmaceuticals Inc. investment picks
ARIAD Pharmaceuticals, Inc .
Sign-up for ARIAD Adopts Shareholder Rights Plan to Preserve Valuable Net Operating Loss Carryforwards and Other Tax Benefits investment picks
2014/1/14
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medinol, Ltd.
Sign-up for ARIAD and Medinol Announce Initiation of Two Registration Trials of the NIRsupreme™ Ridaforolimus-Eluting Stent for Use in Coronary Artery Disease investment picks
2014/4/2
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Hugh M.
Sign-up for ARIAD Announces Appointment of Hugh Cole, Senior Pharmaceutical-Industry Executive, as Chief Business Officer investment picks
2013/10/31
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will change the date of its third quarter 2013 conference call to Tuesday, November 12, 2013, at 8:30 a.m. EST.
Sign-up for ARIAD Announces Change to the Date of Its Third Quarter 2013 Financial Results Conference Call and Webcast to November 12, 2013 investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced results of its review of updated clinical data from the pivotal PACE trial of Iclusig ® (ponatinib) and actions that it is taking following consultations with the U.S. Food and Drug Administration (FDA). The Company is implementing the following actions in its Iclusig clinical development program: Patient enrollment in all clinical studies of Iclusig is being paused, and subject to agreement with the FDA, will be resumed with anticipated changes in dose and other modifications.
Sign-up for ARIAD Announces Changes in the Clinical Development Program of Iclusig investment picks
2014/1/28
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), a specialty pharmaceutical company, today announced that ARIAD has granted STA exclusive rights to commercialize Iclusig ® (ponatinib) in Australia in patients with Philadelphia-positive (Ph+) leukemias.
Sign-up for ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Australia investment picks
2013/10/18
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that it is discontinuing the Phase 3 EPIC ( E valuation of P onatinib versus I matinib in C hronic Myeloid Leukemia) trial of Iclusig ® (ponatinib) in patients with newly diagnosed chronic myeloid leukemia.
Sign-up for ARIAD Announces Discontinuation of the Phase 3 Epic Trial of Iclusig in Patients with Newly Diagnosed Chronic Myeloid Leukemia investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the schedule of several data presentations on Iclusig ® (ponatinib) that will take place at the 55th Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, December 7 to 10, 2013.
Sign-up for ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting investment picks
2014/3/24
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation of a pivotal global Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously treated with crizotinib.
Sign-up for ARIAD Announces Initiation of Pivotal Phase 2 ALTA Trial of AP26113 in Patients with Non-Small Cell Lung Cancer investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced adoption of a positive opinion by the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) on the continued availability of Iclusig ® (ponatinib) in the EU for use in patients in its authorized indications.
Sign-up for ARIAD Announces Positive Opinion by the European Medicines Agency on the Continued Availability of Iclusig in Patients with Leukaemias investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it is reducing approximately 40 percent of its staff positions in the United States following its decision to temporarily suspend the marketing and commercial distribution of Iclusig ® (ponatinib) in the U.S. The reduction in U.S. staff includes positions in all major departments.
Sign-up for ARIAD Announces Reduction in U.S. Workforce as Part of Broad Program to Reduce Operating Expenses investment picks
2013/10/31
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that it is temporarily suspending the marketing and commercial distribution of Iclusig ® (ponatinib), a treatment for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy.
Sign-up for ARIAD Announces Temporary Suspension of Iclusig Marketing in the United States investment picks
2014/1/17
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the commercial availability of Iclusig ® (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States.
Sign-up for ARIAD Announces the Commercial Availability of Iclusig (Ponatinib) for Patients with Refractory Philadelphia-Positive Leukemias in the U.S. investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the U.S. Food and Drug Administration (FDA) has approved revised U.S. Prescribing Information (USPI) and a Risk Evaluation and Mitigation Strategy (REMS) for Iclusig ® (ponatinib) that allows immediate resumption of its marketing and commercial distribution.
Sign-up for ARIAD Announces U.S. Resumption of Marketing and Commercial Distribution of Iclusig (ponatinib) in Refractory Philadelphia-Positive Leukemias investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that updated data from its Phase 1/2 trial of AP26113 , an investigational inhibitor of anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR) and c-ros oncogene 1 (ROS1), will be presented at the European Cancer Congress (the 38 th ESMO, 32 nd ESTRO, 17 th ECCO) being held in Amsterdam, September 27 to October 1, 2013.
Sign-up for ARIAD Announces Updated Data on AP26113 to Be Presented at the European Cancer Congress 2013 Meeting investment picks
2014/2/21
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the appointment of Alexander J.
Sign-up for ARIAD Expands Its Board of Directors with Appointment of Alexander J. Denner, Ph.D. of Sarissa Capital Management investment picks
Former United States Securities and Exchange Commission attorney Willie Briscoe , founder of The Briscoe Law Firm, PLLC , and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit has been filed against Ariad Pharmaceuticals, Inc. (“Ariad” or “Company”) (NasdaqGS: ARIA) and several officers and directors for acts taken during the period of December 12, 2011 to October 8, 2013 (the “Class Period”). Based upon the allegations in the class action, the firms are investigating additional legal claims against the officers and Board of Directors of Ariad.
Sign-up for Ariad Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors investment picks
2013/10/18
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased ARIAD Pharmaceuticals, Inc. (“ARIAD” or the “Company”) (NASDAQ GS:ARIA) stock between December 12, 2011 and October 8, 2013.
Sign-up for ARIAD PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Class Action Against ARIAD Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013 -- ARIA investment picks
2013/9/28
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113 , in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.
Sign-up for ARIAD Presents Updated Phase 1/2 Data on AP26113 in Patients with Non-Small Cell Lung Cancer investment picks
2013/9/4
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced enrollment of fifty percent of the patients planned in its randomized Phase 3 trial of Iclusig ® (ponatinib) in adult patients with newly diagnosed chronic myeloid leukemia (CML). The trial, formally known as EPIC ( E valuation of P onatinib versus I matinib in C hronic Myeloid Leukemia), is designed to provide definitive clinical data to support regulatory approval of ponatinib in treatment-naïve CML patients.
Sign-up for ARIAD Reaches 50 Percent Patient Enrollment in Phase 3 EPIC Trial of Iclusig investment picks
2014/2/25
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments.
Sign-up for ARIAD Reports 2013 Financial Results and Outlines Key Objectives for 2014 investment picks
2013/8/7
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter of 2013, including revenue from Iclusig ® (ponatinib), which is approved by the U.S. Food & Drug Administration and the European Commission.
Sign-up for ARIAD Reports Second Quarter 2013 Financial Results and Development Progress investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: ARI Promotes Bradley J. Smith to Vice President of Product Management to ARIAD Reports Second Quarter 2013 Financial Results and Development Progress
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity